Human Papillomavirus Genotype Prevalence in Invasive Vaginal Cancer from a Registry-Based Population
Published Date:Apr 2014
Source:Obstet Gynecol. 123(4):817-821.
Pubmed Central ID:PMC4009490
Funding:1U58DP000807-03/DP/NCCDPHP CDC HHS/United States
5U58DP000810-5/DP/NCCDPHP CDC HHS/United States
5U58DP000812-5/DP/NCCDPHP CDC HHS/United States
5U58DP000844-5/DP/NCCDPHP CDC HHS/United States
N01 PC035139/PC/NCI NIH HHS/United States
N01-PC-2010-00035/PC/NCI NIH HHS/United States
N01-PC-35137/PC/NCI NIH HHS/United States
N01-PC-35139/PC/NCI NIH HHS/United States
N01-PC-35143/PC/NCI NIH HHS/United States
N01PC35137/CA/NCI NIH HHS/United States
N01PC35143/CA/NCI NIH HHS/United States
P30 CA071789/CA/NCI NIH HHS/United States
P30 CA086862/CA/NCI NIH HHS/United States
P30 CA177558/CA/NCI NIH HHS/United States
To describe the human papillomavirus (HPV) genotype distribution in invasive vaginal cancers diagnosed prior to the introduction of the HPV vaccine, and evaluate if survival differed by HPV status.
Four population-based registries and three residual tissue repositories provided formalin-fixed, paraffin-embedded tissue from microscopically confirmed primary vaginal cancer cases diagnosed between 1994 and 2005 that were tested by L1 consensus polymerase chain reaction with type-specific hybridization in a central laboratory. Clinical, demographic, and all-cause survival data were assessed by HPV status.
Sixty cases of invasive vaginal cancer were included. HPV was detected in 75% (45) and 25% (15) were HPV negative. HPV 16 was most frequently detected (55%, 33/60) followed by HPV 33 (18.3%, 11/60). Only one case was positive for HPV 18 (1.7%) Multiple types were detected in 15% of the cases. Vaginal cancers in women < 60 were more likely to be HPV 16 or HPV 18 positive (HPV 16/18) than older women; 77.3% vs. 44.7% (P = .038). The median age at diagnosis was younger in the HPV16/18 (59 years) group vs. other HPV positive (68 years) and no HPV (77 years) (P =.003). The HPV distribution did not significantly vary by race or ethnicity or place of residence. The 5-year unadjusted all-cause survival was 57.4% for women with HPV-positive vaginal cancers vs. 35.7% among those with HPV-negative tumors (p=0.243).
Three quarters of all vaginal cancers in the United States had HPV detected, much higher than previously found , and 57% could be prevented by current HPV vaccines, .
text/plain image/gif image/jpeg image/gif image/jpeg
You May Also Like: